Edit
Cephalon
http://www.cephalon.com/Last activity: 08.03.2024
Probably Closed - Reference to pause_roadblock
Salmedix was a start-up biotechnology firm focused on discovering and developing minimally-toxic therapies to treat cancers, particularly those that affect the growing global geriatric population. The company was acquired by Cephalon in May 2005.
Investors 3
Mentions in press and media 3
| Date | Title | Description |
| 08.03.2024 | Epilepsy Surgery Market Worth $1483.5 Mn by 2030 Driven by Increasing Prevalence of Epilepsy & Improved Diagnostic Tools | Epilepsy Surgery Market Epilepsy Surgery Market Analysis, Trends, Industry Overview, and Growth Outlook AUSTIN, TEXAS, UNITED STATES, March 8, 2024 /EINPresswire.com/ -- The Global Epilepsy Surgery Market is expected to reach 1483.5 million... |
| 08.06.2011 | FDA’s REMS program puts BDSI at a disadvantage in cancer drug market | BDSI has been working with the FDA on changes to get its lead product on the same footing as its competitors. While BDSI had hoped to finish those changes in the second quarter, now it looks like it will be a little bit longer. Vice preside... |
| - | FDA’s REMS program puts BDSI at a disadvantage in cancer drug market | Commercializing a new drug in the face of strict U.S. Food and Drug Administration guidelines is tough. It’s even tougher when direct competitors don’t have those same limits. That’s the situation facing Raleigh, North Carolina-based BioDel... |